CA1341644C - Molecules d'adn recombinant et procede pour leur production - Google Patents

Molecules d'adn recombinant et procede pour leur production

Info

Publication number: CA1341644C
Authority: CA; Canada
Prior art keywords: hepatitis; hbv; antigen; recombinant dna; polypeptide
Prior art date: 1978-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA342497A

Other languages

English (en)

Inventor

Kenneth Murray

Heinz Ernst Schaller

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biogen MA Inc

Original Assignee

Biogen MA Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-12-22

Filing date

1979-12-21

Publication date

2023-03-07

1979-12-21 Application filed by Biogen MA Inc filed Critical Biogen MA Inc

1979-12-21 Priority to CA342497A priority Critical patent/CA1341644C/fr

2023-03-07 Application granted granted Critical

2023-03-07 Publication of CA1341644C publication Critical patent/CA1341644C/fr

Status Active legal-status Critical Current

2040-03-07 Anticipated expiration legal-status Critical

Links

108020004511 Recombinant DNA Proteins 0.000 title claims abstract description 155
238000000034 method Methods 0.000 title claims abstract description 85
238000004519 manufacturing process Methods 0.000 title claims abstract description 34
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 191
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 166
229920001184 polypeptide Polymers 0.000 claims abstract description 159
241000700721 Hepatitis B virus Species 0.000 claims abstract description 78
208000015181 infectious disease Diseases 0.000 claims abstract description 32
239000000203 mixture Substances 0.000 claims abstract description 24
230000004936 stimulating effect Effects 0.000 claims abstract description 5
108020004414 DNA Proteins 0.000 claims description 143
239000000427 antigen Substances 0.000 claims description 138
108091007433 antigens Proteins 0.000 claims description 138
102000036639 antigens Human genes 0.000 claims description 138
210000004027 cell Anatomy 0.000 claims description 120
102000053602 DNA Human genes 0.000 claims description 109
239000012634 fragment Substances 0.000 claims description 92
208000002672 hepatitis B Diseases 0.000 claims description 88
230000014509 gene expression Effects 0.000 claims description 86
101710132601 Capsid protein Proteins 0.000 claims description 74
108091028043 Nucleic acid sequence Proteins 0.000 claims description 57
230000001580 bacterial effect Effects 0.000 claims description 40
241000588724 Escherichia coli Species 0.000 claims description 31
150000001413 amino acids Chemical class 0.000 claims description 30
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 29
238000010367 cloning Methods 0.000 claims description 29
239000002245 particle Substances 0.000 claims description 29
241000282414 Homo sapiens Species 0.000 claims description 28
239000003981 vehicle Substances 0.000 claims description 24
230000001131 transforming effect Effects 0.000 claims description 23
241000288906 Primates Species 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 22
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 16
210000002966 serum Anatomy 0.000 claims description 13
241001465754 Metazoa Species 0.000 claims description 12
238000001514 detection method Methods 0.000 claims description 11
241001131785 Escherichia coli HB101 Species 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 8
235000014469 Bacillus subtilis Nutrition 0.000 claims description 7
101710125418 Major capsid protein Proteins 0.000 claims description 7
101710094648 Coat protein Proteins 0.000 claims description 6
241000233866 Fungi Species 0.000 claims description 6
102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 6
101710141454 Nucleoprotein Proteins 0.000 claims description 6
101710083689 Probable capsid protein Proteins 0.000 claims description 6
241000702208 Shigella phage SfX Species 0.000 claims description 6
238000012986 modification Methods 0.000 claims description 6
230000004048 modification Effects 0.000 claims description 6
229960005486 vaccine Drugs 0.000 claims description 6
244000063299 Bacillus subtilis Species 0.000 claims description 5
241000196324 Embryophyta Species 0.000 claims description 5
241000702374 Enterobacteria phage fd Species 0.000 claims description 5
108700039691 Genetic Promoter Regions Proteins 0.000 claims description 5
241000589516 Pseudomonas Species 0.000 claims description 5
230000000638 stimulation Effects 0.000 claims description 5
239000013598 vector Substances 0.000 claims description 5
102000004506 Blood Proteins Human genes 0.000 claims 21
108010017384 Blood Proteins Proteins 0.000 claims 21
239000013599 cloning vector Substances 0.000 claims 20
230000004481 post-translational protein modification Effects 0.000 claims 20
239000013604 expression vector Substances 0.000 claims 19
238000012258 culturing Methods 0.000 claims 18
241000124008 Mammalia Species 0.000 claims 13
238000004113 cell culture Methods 0.000 claims 11
210000005253 yeast cell Anatomy 0.000 claims 9
238000009007 Diagnostic Kit Methods 0.000 claims 8
210000004962 mammalian cell Anatomy 0.000 claims 8
241000304886 Bacilli Species 0.000 claims 4
210000003527 eukaryotic cell Anatomy 0.000 claims 4
230000002068 genetic effect Effects 0.000 claims 4
210000004748 cultured cell Anatomy 0.000 claims 3
230000016784 immunoglobulin production Effects 0.000 claims 3
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 claims 1
108010087924 alanylproline Proteins 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 149
230000009385 viral infection Effects 0.000 abstract description 4
239000002773 nucleotide Substances 0.000 description 62
125000003729 nucleotide group Chemical group 0.000 description 61
239000013612 plasmid Substances 0.000 description 34
230000008569 process Effects 0.000 description 26
102000004169 proteins and genes Human genes 0.000 description 26
239000004098 Tetracycline Substances 0.000 description 23
229960002180 tetracycline Drugs 0.000 description 23
229930101283 tetracycline Natural products 0.000 description 23
235000019364 tetracycline Nutrition 0.000 description 23
150000003522 tetracyclines Chemical class 0.000 description 22
108091008146 restriction endonucleases Proteins 0.000 description 21
229960000723 ampicillin Drugs 0.000 description 15
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 15
239000000047 product Substances 0.000 description 15
241000700605 Viruses Species 0.000 description 13
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
108091081024 Start codon Proteins 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
229920001817 Agar Polymers 0.000 description 9
108010087702 Penicillinase Proteins 0.000 description 9
239000008272 agar Substances 0.000 description 9
238000009396 hybridization Methods 0.000 description 9
238000003780 insertion Methods 0.000 description 9
230000037431 insertion Effects 0.000 description 9
108020004705 Codon Proteins 0.000 description 8
241000282412 Homo Species 0.000 description 8
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
230000014616 translation Effects 0.000 description 8
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000029087 digestion Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
238000013519 translation Methods 0.000 description 7
238000011534 incubation Methods 0.000 description 6
229950009506 penicillinase Drugs 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
230000009466 transformation Effects 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
230000027455 binding Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000008188 pellet Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
238000012216 screening Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
102100031780 Endonuclease Human genes 0.000 description 4
108010042407 Endonucleases Proteins 0.000 description 4
108060002716 Exonuclease Proteins 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000010276 construction Methods 0.000 description 4
102000013165 exonuclease Human genes 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000000605 extraction Methods 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
229910001629 magnesium chloride Inorganic materials 0.000 description 4
244000005700 microbiome Species 0.000 description 4
230000035772 mutation Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
108010077805 Bacterial Proteins Proteins 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
108010061982 DNA Ligases Proteins 0.000 description 3
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 3
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
101710142246 External core antigen Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
108010076181 Proinsulin Proteins 0.000 description 3
108091006629 SLC13A2 Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000007170 pathology Effects 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
150000002972 pentoses Chemical class 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000011282 treatment Methods 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
235000011178 triphosphate Nutrition 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
206010013710 Drug interaction Diseases 0.000 description 2
241000588722 Escherichia Species 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
101000976075 Homo sapiens Insulin Proteins 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
108700005078 Synthetic Genes Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
229940000425 combination drug Drugs 0.000 description 2
238000011109 contamination Methods 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000034994 death Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000000951 immunodiffusion Effects 0.000 description 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
-1 nucleoside triphosphates Chemical class 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
241000194108 Bacillus licheniformis Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
241000701533 Escherichia virus T4 Species 0.000 description 1
101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
101710121996 Hexon protein p72 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
108010031099 Mannose Receptor Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108010075344 Tryptophan synthase Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
101150094493 fic gene Proteins 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
235000013905 glycine and its sodium salt Nutrition 0.000 description 1
239000004247 glycine and its sodium salt Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
208000020673 hypertrichosis-acromegaloid facial appearance syndrome Diseases 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000001320 lysogenic effect Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
238000007747 plating Methods 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940029258 sodium glycinate Drugs 0.000 description 1
WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA342497A 1978-12-22 1979-12-21 Molecules d'adn recombinant et procede pour leur production Active CA1341644C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA342497A CA1341644C (fr)	1978-12-22	1979-12-21	Molecules d'adn recombinant et procede pour leur production

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GB7849907		1978-12-22
GB49907/78		1978-12-22
GB7850039		1978-12-27
GB50039/78		1978-12-27
GB79/37910		1979-11-01
GB7937910		1979-11-01
CA342497A CA1341644C (fr)	1978-12-22	1979-12-21	Molecules d'adn recombinant et procede pour leur production

Publications (1)

Publication Number	Publication Date
CA1341644C true CA1341644C (fr)	2023-03-07

Family

ID=85476377

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA342497A Active CA1341644C (fr)	1978-12-22	1979-12-21	Molecules d'adn recombinant et procede pour leur production

Country Status (1)

Country	Link
CA (1)	CA1341644C (fr)

1979
- 1979-12-21 CA CA342497A patent/CA1341644C/fr active Active

Publication	Publication Date	Title
EP0013828B2 (fr)	1996-03-20	ADN recombinant, hÔtes transformés avec le dit-ADN recombinant et procédés pourla préparation des polypeptides
US5314808A (en)	1994-05-24	Method for the transformation of cells, particularly eukaryotes by a DNA originating from viruses of hepatitis, more particularly from virus of a B viral hepatitis, and preparations containing the expression products of said DNAs
JPS6255088A (ja)	1987-03-10	組換えｄｎａ技術によるｂ型肝炎表面抗原
EP0182442B1 (fr)	1990-07-11	Molécules de l'ADN recombinant et procédé pour leur production
EP0068719A2 (fr)	1983-01-05	Acides désoxyribonucléiques, leur production et utilisation
US4820642A (en)	1989-04-11	Amplified expression vector
US4853333A (en)	1989-08-01	Production of rotavirus in yeast
EP0105141A2 (fr)	1984-04-11	Molécules D'ADN recombinantes, procédé pour leur préparation, leur utilisation dans la production de l'antigène de surface de l'hépatite B (HBsAg) et compositions pharmaceutiques contenant cet HBsAg
US6268122B1 (en)	2001-07-31	Recombinant DNA molecules and their method of production
US4859465A (en)	1989-08-22	Vaccine capable of eliciting multivalent antibodies
CA1341644C (fr)	2023-03-07	Molecules d'adn recombinant et procede pour leur production
EP0218474A2 (fr)	1987-04-15	ADN et polypeptide
JPH08275781A (ja)	1996-10-22	Ｃ型肝炎ウイルスの蛋白質に由来するポリペプチド、該ポリペプチドを含有するテストキットおよびｃ型肝炎ウイルス感染予防ワクチン
EP0154587A2 (fr)	1985-09-11	Fragments d'ADN codant pour des peptides capables d'induire in vivo la synthèse d'anticorps contre le virus de l'hépatite A
FI95045B (fi)	1995-08-31	Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut
HRP940048A2 (en)	1997-08-31	Process for the preparation of polypeptides having the antigenicity or antigen specificity of hepatitis b viral antigens
JPH0859695A (ja)	1996-03-05	新規ｄｎａおよびポリペプチド
FI95726B (fi)	1995-11-30	Diagnostiset menetelmät ja määrityssarjat, joissa käytetään yhdistelmä-DNA-tekniikalla muodostettua hepatitis B -viruksen pinta-antigeenia
SI7913127A8 (sl)	1994-12-31	Rekombinantne dna molekule in postopek za njihovo proizvodnjo
HU196236B (en)	1988-10-28	Process for producing polypeptides showing hepatitis b virus antigenicity
MXPA02010880A (es)	2003-03-27	Virus centinela ii.
JPH104983A (ja)	1998-01-13	新規ｄｎａおよびそれを用いたポリペプチドの製造法